FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969841034> ?p ?o ?g. }

• W2969841034 endingPage "1386" @default.
• W2969841034 startingPage "1386" @default.
• W2969841034 abstract "Before 2009, only 4 self-administered disease-modifying therapies (DMTs) were approved for the treatment of multiple sclerosis (MS). Since then, 7 new agents have entered the market.To assess trends in prices, market share, and spending on self-administered DMTs for MS in Medicare Part D from 2006 through 2016.This cohort study used claims data from 2006 through 2016 from a 5% random sample of Medicare beneficiaries (a mean of 2.8 million Medicare beneficiaries per year). All prescription claims for self-administered DMTs for MS (glatiramer acetate, interferon beta-1a, interferon beta-1b, fingolimod hydrochloride, teriflunomide, dimethyl fumarate, and peginterferon beta-1a) were extracted throughout the study period.The main outcomes were the annual cost of treatment with each medication, based on Medicare Part D prescription claims gross costs and US Food and Drug Administration-approved recommended dosing; market share of each medication, defined as the proportion of pharmaceutical spending accounted by every drug; and pharmaceutical spending per 1000 Medicare beneficiaries for all drugs. The relative contributions of Medicare Part D Plans' payments, Medicare catastrophic coverage payments, low-income cost-sharing subsidies, patients' out-of-pocket costs, manufacturers' coverage gap discounts, and other payments toward pharmaceutical spending were further quantified.Annual costs of treatment with self-administered DMTs for MS more than quadrupled from 2006 to 2016, from a mean (SD) of $18 660 ($1177) to $75 847 ($16 956) and at a mean rate of 12.8% every year. Brand-name glatiramers accounted for the largest market share across the study period, ranging between $25 552 of $79 411 per 1000 Medicare beneficiaries (32.2%) and $10 342 of $21 365 per 1000 Medicare beneficiaries (48.4%). Platform therapies experienced a substantial drop from 2006 to 2016 in favor of newer therapies, with decreases in the market shares of brand-name glatiramers (per 1000 Medicare beneficiaries: $2861 of $7794 [36.7%] to $25 552 of $79 411 [32.2%]), interferon beta-1a (30 µg; per 1000 Medicare beneficiaries: $2521 of $7794 [32.3%] to $11 298 of $79 411 [14.2%]), interferon beta-1b (Betaseron; per 1000 Medicare beneficiaries: $1460 of $7794 [18.7%] to $3588 of $79 411 [4.5%]), and interferon beta-1a (8.8/22/44 µg; per 1000 Medicare beneficiaries: $951 of $7794 [12.2%] to $6588 of $79 411 [8.3%]) and increases in fingolimod (to $6311 of $79 411 per 1000 Medicare beneficiaries [7.9%]), teriflunomide (to $7177 of $79 411 per 1000 Medicare beneficiaries [9.0%]), and dimethyl fumarate (to $15 262 of $79 411 per 1000 Medicare beneficiaries [19.2%]). Throughout the study period, pharmaceutical spending per 1000 beneficiaries increased 10.2-fold (from $7794 to $79 411), and out-of-pocket patient spending per 1000 beneficiaries increased 7.2-fold (from $372 to $2673). The relative contribution of federal payments toward pharmaceutical spending increased from $5335 of $7794 (68.5%) to $58 620 to $79 411 (73.8%).Per this analysis, prices of self-administered DMTs for MS increased dramatically between 2006 and 2016. This resulted in a 7.2-fold increase in patient out-of-pocket costs." @default.
• W2969841034 created "2019-08-29" @default.
• W2969841034 creator A5008785679 @default.
• W2969841034 creator A5012227398 @default.
• W2969841034 creator A5028183261 @default.
• W2969841034 creator A5032962162 @default.
• W2969841034 creator A5060167116 @default.
• W2969841034 creator A5089117734 @default.
• W2969841034 date "2019-11-01" @default.
• W2969841034 modified "2023-10-16" @default.
• W2969841034 title "Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D" @default.
• W2969841034 cites W1542445145 @default.
• W2969841034 cites W1988243157 @default.
• W2969841034 cites W2151516700 @default.
• W2969841034 cites W2748489847 @default.
• W2969841034 cites W28024029 @default.
• W2969841034 cites W2907948509 @default.
• W2969841034 cites W2914141021 @default.
• W2969841034 cites W2914634417 @default.
• W2969841034 cites W2942809567 @default.
• W2969841034 doi "https://doi.org/10.1001/jamaneurol.2019.2711" @default.
• W2969841034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6714023" @default.
• W2969841034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31449293" @default.
• W2969841034 hasPublicationYear "2019" @default.
• W2969841034 type Work @default.
• W2969841034 sameAs 2969841034 @default.
• W2969841034 citedByCount "26" @default.
• W2969841034 countsByYear W29698410342019 @default.
• W2969841034 countsByYear W29698410342020 @default.
• W2969841034 countsByYear W29698410342021 @default.
• W2969841034 countsByYear W29698410342022 @default.
• W2969841034 countsByYear W29698410342023 @default.
• W2969841034 crossrefType "journal-article" @default.
• W2969841034 hasAuthorship W2969841034A5008785679 @default.
• W2969841034 hasAuthorship W2969841034A5012227398 @default.
• W2969841034 hasAuthorship W2969841034A5028183261 @default.
• W2969841034 hasAuthorship W2969841034A5032962162 @default.
• W2969841034 hasAuthorship W2969841034A5060167116 @default.
• W2969841034 hasAuthorship W2969841034A5089117734 @default.
• W2969841034 hasBestOaLocation W29698410342 @default.
• W2969841034 hasConcept C10138342 @default.
• W2969841034 hasConcept C104863432 @default.
• W2969841034 hasConcept C118552586 @default.
• W2969841034 hasConcept C144133560 @default.
• W2969841034 hasConcept C16051113 @default.
• W2969841034 hasConcept C160735492 @default.
• W2969841034 hasConcept C162324750 @default.
• W2969841034 hasConcept C2426938 @default.
• W2969841034 hasConcept C2776036978 @default.
• W2969841034 hasConcept C2776291444 @default.
• W2969841034 hasConcept C2777703276 @default.
• W2969841034 hasConcept C2778858636 @default.
• W2969841034 hasConcept C2779703844 @default.
• W2969841034 hasConcept C2780640218 @default.
• W2969841034 hasConcept C50522688 @default.
• W2969841034 hasConcept C512399662 @default.
• W2969841034 hasConcept C71924100 @default.
• W2969841034 hasConcept C98274493 @default.
• W2969841034 hasConceptScore W2969841034C10138342 @default.
• W2969841034 hasConceptScore W2969841034C104863432 @default.
• W2969841034 hasConceptScore W2969841034C118552586 @default.
• W2969841034 hasConceptScore W2969841034C144133560 @default.
• W2969841034 hasConceptScore W2969841034C16051113 @default.
• W2969841034 hasConceptScore W2969841034C160735492 @default.
• W2969841034 hasConceptScore W2969841034C162324750 @default.
• W2969841034 hasConceptScore W2969841034C2426938 @default.
• W2969841034 hasConceptScore W2969841034C2776036978 @default.
• W2969841034 hasConceptScore W2969841034C2776291444 @default.
• W2969841034 hasConceptScore W2969841034C2777703276 @default.
• W2969841034 hasConceptScore W2969841034C2778858636 @default.
• W2969841034 hasConceptScore W2969841034C2779703844 @default.
• W2969841034 hasConceptScore W2969841034C2780640218 @default.
• W2969841034 hasConceptScore W2969841034C50522688 @default.
• W2969841034 hasConceptScore W2969841034C512399662 @default.
• W2969841034 hasConceptScore W2969841034C71924100 @default.
• W2969841034 hasConceptScore W2969841034C98274493 @default.
• W2969841034 hasIssue "11" @default.
• W2969841034 hasLocation W29698410341 @default.
• W2969841034 hasLocation W29698410342 @default.
• W2969841034 hasLocation W29698410343 @default.
• W2969841034 hasOpenAccess W2969841034 @default.
• W2969841034 hasPrimaryLocation W29698410341 @default.
• W2969841034 hasRelatedWork W1532617462 @default.
• W2969841034 hasRelatedWork W2095082788 @default.
• W2969841034 hasRelatedWork W2316458168 @default.
• W2969841034 hasRelatedWork W2739756297 @default.
• W2969841034 hasRelatedWork W2969841034 @default.
• W2969841034 hasRelatedWork W2971309441 @default.
• W2969841034 hasRelatedWork W3046483319 @default.
• W2969841034 hasRelatedWork W4235416836 @default.
• W2969841034 hasRelatedWork W4238757216 @default.
• W2969841034 hasRelatedWork W4283512998 @default.
• W2969841034 hasVolume "76" @default.
• W2969841034 isParatext "false" @default.
• W2969841034 isRetracted "false" @default.
• W2969841034 magId "2969841034" @default.
• W2969841034 workType "article" @default.